Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Structural changes in neuroanatomical subregions can be measured using serial magnetic resonance imaging scans, and provide powerful biomarkers for detecting and monitoring Alzheimer's disease. The Alzheimer's Disease Neuroimaging Initiative (ADNI) has made a large database of longitudinal scans available, with one of its primary goals being to explore the utility of structural change measures for assessing treatment effects in clinical trials of putative disease‐modifying therapies. Several ADNI‐funded research laboratories have calculated such measures from the ADNI database and made their results publicly available. Here, using sample size estimates, we present a comparative analysis of the overall results that come from the application of each laboratory's extensive processing stream to the ADNI database. Obtaining accurate measures of change requires correcting for potential bias due to the measurement methods themselves; and obtaining realistic sample size estimates for treatment response, based on longitudinal imaging measures from natural history studies such as ADNI, requires calibrating measured change in patient cohorts with respect to longitudinal anatomical changes inherent to normal aging. We present results showing that significant longitudinal change is present in healthy control subjects who test negative for amyloid‐β pathology. Therefore, sample size estimates as commonly reported from power calculations based on total structural change in patients, rather than change in patients relative to change in healthy controls, are likely to be unrealistically low for treatments targeting amyloid‐related pathology. Of all the measures publicly available in ADNI, thinning of the entorhinal cortex quantified with the Quarc methodology provides the most powerful change biomarker. Hum Brain Mapp, 2012. © 2011 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · cited 6×
“Proposed models of the trajectories of different AD biomarkers [Aisen et al., 2010; Frisoni et al., 2010; Jack et al., 2010] postulate that Ab pathology is the earliest detectable sign of AD pathology, and may be apparent a decade or more before other signs of AD occur, such as neurodegeneration…”
BackgroundMethodResultInfluentialAlzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Evaluation of 14 nonlinear deformation algorithms applied to human brain MRI registration
Klein, A., Andersson, J., Ardekani, B. A., Ashburner, J., Avants, B., Chiang, M.-C., Christensen, G. E., Collins, D. L., Gee, J., Hellier, P., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.12.037 · Cited by 2,227
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Dale, A. M., & Sereno, M. I. (1993) · Journal of Cognitive Neuroscience · doi:10.1162/jocn.1993.5.2.162 · Cited by 2,003 · cited 1×
“…in our laboratory) [Holland and Dale, 2011; Holland et al., 2009], (2) FreeSurfer Longitudinal v.4.4, (3) FreeSurfer Cross-sectional v.4.3 [Dale and Sereno, 1993; Dale et al., 1999; Fischl et al., 1999, 2002; Jack et al., 2010], (4) BSI [Freeborough and Fox, 1997; Leung et al., 2010], and…”
InfluentialSelf-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 4×
“Pathological levels of cortical Ab can be assessed directly through positron emission tomography (PET) imaging of amyloidsensitive ligands [Rabinovici and Jagust, 2009] or indirectly through cerebrospinal fluid levels of Ab42 [Blennow et al., 2010].”
BackgroundInfluentialHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 2×
“…clinical improvement in this trial largely may have been precluded because the patient cohort was at a relatively advanced stage of the disease [Holmes et al., 2008; Hyman, 2011], this outcome nevertheless argues in favor of analyzing subregional, in particular cortical, change rather than…”
ResultPrediction of AD with MRI-based hippocampal volume in mild cognitive impairment
Jack, C. R., Petersen, R. C., Xu, Y. C., O’Brien, P. C., Smith, G. E., Ivnik, R. J., Boeve, B. F., Waring, S. C., Tangalos, E. G., & Kokmen, E. (1999) · Neurology · doi:10.1212/wnl.52.7.1397 · Cited by 1,404 · cited 1×
“They are predictive of clinical decline and conversion to AD in individuals with mild cognitive impairment (MCI) [Fan et al., 2008; Jack et al., 1999, 2004; Kovacevic et al., 2009; McEvoy et al., 2011; Vemuri et al., 2009].”
BackgroundClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 1×
“Current research suggests, however, that only 18% of cognitively healthy older individuals aged 60–69 show signs of amyloid-b (Ab) pathology, one of the key necessary features for AD, rising to 65% in those over 80 years [Rowe et al., 2010].”
BackgroundPost-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827 · cited 3×
“Atrophy measures in neuroanatomical subregions correlate well with disease stage determined from histopathology [Vemuri et al., 2008], and with clinical measures of disease severity [Jack et al., 2004; McDonald et al., 2009].”
BackgroundMultimodal techniques for diagnosis and prognosis of Alzheimer's disease
Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009) · Nature · doi:10.1038/nature08538 · Cited by 702 · cited 2×
“…important to point out that longitudinal MRI measures as provided by ADNI are also being used in the comparative investigation of disease-related trajectories of various AD biomarkers [Caroli and Frisoni, 2010; Frisoni et al., 2010; Jack et al., 2010; Perrin et al., 2009; Trojanowski et al., 2010].”
BackgroundOne-Year Brain Atrophy Evident in Healthy Aging
Fjell, A. M., Walhovd, K. B., Fennema-Notestine, C., McEvoy, L. K., Hagler, D. J., Holland, D., Brewer, J. B., & Dale, A. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3252-09.2009 · Cited by 692
Self-citationNeuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · cited 1×
“…highly unlikely to be in a preclinical stage of AD—and indeed since many elderly HCs have elevated plaque burden while remaining cognitively normal [Price et al., 2009], it might be that ‘‘Alzheimer’s is not a part of normal aging any more than breaking your hip is a part of normal aging’’…”
BackgroundNeuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease
Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596
Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD
Fotenos, A. F., Snyder, A. Z., Girton, L. E., Morris, J. C., & Buckner, R. L. (2005) · Neurology · doi:10.1212/01.wnl.0000154530.72969.11 · Cited by 579
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550 · cited 2×
“…of subjects who were antibody responders than in the placebo group, a result possibly due to brain hydration state related to therapy, or to negative effects of the vaccination on fiber or white matter volume, and that was not reflected in worsening cognitive performance [Fox et al., 2005].”
BackgroundChételat, G., Landeau, B., Eustache, F., Mézenge, F., Viader, F., de la Sayette, V., Desgranges, B., & Baron, J.-C. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.05.015 · Cited by 526 · cited 2×
“Official ADNI data for VoxelBased Morphometry [Alexander et al., 2010; Ashburner and Friston, 2000; Chetelat et al., 2005; Tzourio-Mazoyer et al., 2002] did not yield meaningful results and so was not included in our analysis.”
ResultFan, Y., Batmanghelich, N., Clark, C. M., & Davatzikos, C. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.10.031 · Cited by 477 · cited 1×
“They are predictive of clinical decline and conversion to AD in individuals with mild cognitive impairment (MCI) [Fan et al., 2008; Jack et al., 1999, 2004; Kovacevic et al., 2009; McEvoy et al., 2011; Vemuri et al., 2009].”
BackgroundNeuropathologic Substrate of Mild Cognitive Impairment
Markesbery, W. R., Schmitt, F. A., Kryscio, R. J., Davis, D. G., Smith, C. D., & Wekstein, D. R. (2006) · Archives of Neurology · doi:10.1001/archneur.63.1.38 · Cited by 460 · cited 2×
“…amygdala (N ¼ 366 CI ¼ [264 549] for MCI-HC, N ¼ 132 CI ¼ [94 205] for AD-HC) which suffers from a significant increase in the numbers of both neuritic plaques and NFTs when transitioning from HC to amnestic MCI, and again when transitioning from amnestic MCI to early AD [Markesbery et al., 2006].”
BackgroundFagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353
Hippocampal neurons in pre-clinical Alzheimer's disease.
West, M. J., Kawas, C. H., Stewart, W. F., Rudow, G. L., & Troncoso, J. C. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.005 · Cited by 317 · cited 2×
“, 2001] and hippocampal [West et al., 2004] neuron counts—even in CA1, the hippocampal sector most affected by neuron loss in the early stages of AD— between cognitively normal subjects essentially free of amyloid pathology and those exhibiting significant amounts of amyloid deposition, to a degree consistent with a n…”
ResultRegional rates of neocortical atrophy from normal aging to early Alzheimer disease
McDonald, C. R., McEvoy, L. K., Gharapetian, L., Fennema-Notestine, C., Hagler, D. J., Holland, D., Koyama, A., Brewer, J. B., & Dale, A. M. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b16431 · Cited by 299
Self-citationSex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans
Hua, X., Hibar, D. P., Lee, S., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.033 · Cited by 234
Subregional neuroanatomical change as a biomarker for Alzheimer's disease
Holland, D., Brewer, J. B., Hagler, D. J., Fennema-Notestine, C., Dale, A. M., Initiative, T. A. D. N., Weiner, M., Thal, L., Petersen, R., Jack, C. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906053106 · Cited by 210 · cited 9×
“Power calculations, modeling linear change over time, were performed for each methodology with standard methods briefly described in [Holland et al., 2009], using all available timepoints through 36-months for each subject.”
BackgroundMethodResultInfluentialSelf-citationBoosting power for clinical trials using classifiers based on multiple biomarkers
Kohannim, O., Hua, X., Hibar, D. P., Lee, S., Chou, Y.-Y., Toga, A. W., Jack, C. R., Weiner, M. W., & Thompson, P. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.022 · Cited by 190 · cited 4×
“…for neuroimaging outcome measures make this assumption implicitly [Beckett et al., 2010; Cummings, 2010; Ho et al., 2010; Hua et al., 2009, 2010; Kohannim et al., 2010; Lorenzi et al., 2010; Nestor et al., 2008; Risacher et al., 2010; Schuff et al., 2009; Vemuri et al., 2010], with a few…”
BackgroundMethodInfluentialVemuri, P., Whitwell, J. L., Kantarci, K., Josephs, K. A., Parisi, J. E., Shiung, M. S., Knopman, D. S., Boeve, B. F., Petersen, R. C., Dickson, D. W., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.05.012 · Cited by 172
Larger temporal volume in elderly with high versus low beta-amyloid deposition
Chételat, G., Villemagne, V. L., Pike, K. E., Baron, J.-C., Bourgeat, P., Jones, G., Faux, N. G., Ellis, K. A., Salvado, O., Szoeke, C., et al. (2010) · Brain · doi:10.1093/brain/awq187 · Cited by 159 · cited 1×
“…for differences in atrophy rates in AD-vulnerable regions between Ab-positive and Ab-negative healthy older adults (or healthy older controls, HCs) [Chetelat et al., 2010; Fjell et al., 2010], though using variants of Boundary Shift Integral (BSI) for whole brain, ventricles, and hippocampus, a…”
MethodSerial MRI and CSF biomarkers in normal aging, MCI, and AD
Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Aisen, P. S., Weiner, M., Petersen, R. C., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e7ca82 · Cited by 154
Hua, X., Lee, S., Yanovsky, I., Leow, A. D., Chou, Y.-Y., Ho, A. J., Gutman, B., Toga, A. W., Jack, C. R., Bernstein, M. A., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.07.011 · Cited by 145 · cited 2×
“…sample size estimates for neuroimaging outcome measures make this assumption implicitly [Beckett et al., 2010; Cummings, 2010; Ho et al., 2010; Hua et al., 2009, 2010; Kohannim et al., 2010; Lorenzi et al., 2010; Nestor et al., 2008; Risacher et al., 2010; Schuff et al., 2009; Vemuri et al.,…”
BackgroundMethod
Cited by
Within-subject template estimation for unbiased longitudinal image analysis
Reuter, M., Schmansky, N. J., Rosas, H. D., & Fischl, B. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.02.084 · Cited by 2,356
Image processing and analysis methods for the Adolescent Brain Cognitive Development Study
Hagler, D. J., Hatton, S., Cornejo, M. D., Makowski, C., Fair, D. A., Dick, A. S., Sutherland, M. T., Casey, B. J., Barch, D. M., Harms, M. P., et al. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116091 · Cited by 1,088
Self-citationThe Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Fjell, A. M., McEvoy, L., Holland, D., Dale, A. M., & Walhovd, K. B. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.004 · Cited by 799
“…studies, several have found modest acceleration of regional decline with increasing age (Raz et al., 2004a,b, 2005, 2010; Du et al., 2006; Driscoll et al., 2009; Fjell et al., 2009a; Schuff et al., 2010; Thambisetty et al., 2010; Holland et al., 2012a; Taki et al., 2013; Pfefferbaum et al., 2013).”
BackgroundSelf-citationA randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
Turner, R. S., Thomas, R. G., Craft, S., van Dyck, C. H., Mintzer, J., Reynolds, B. A., Brewer, J. B., Rissman, R. A., Raman, R., Aisen, P. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002035 · Cited by 736
Metadata
- Authors
- Holland, D., McEvoy, L. K., Dale, A. M., & Initiative, T. A. D. N.
- Venue
- Human Brain Mapping
- Publisher
- Wiley
- Published
- 2011-08-09
- Volume
- 33
- Issue
- 11
- Pages
- 2586-2602
- ISSN
- 1065-9471 (ISSN-L)
- 1097-0193
- OpenAlex
- W1977832043
- Cited by
- 84
- References
- 33
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.